drugset
drugset / Trial / NCT07354516

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516 ↗

Phase 2/3 Active not recruiting 60 enrolled Qlaris Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Timeline

Start
2026-03-18
Primary completion
2026-07-24
Completion
2026-07-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Topical
Subject QLS-111-FDC Unknown — Topical

Indications

ocular hypertension open-angle glaucoma